Oncopeptides Q4: Germany Drives Sales - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Oncopeptides Q4: Germany Drives Sales - Redeye

{newsItem.title}

Revenues in Q4 came in at SEK10m, slightly softer than we had estimated, albeit still showing growth, mainly in Germany. The number of prescribers increased, boding well for H1 2025. Oncopeptides is also making progress in licensing discussions and its preclinical programmes. We make moderate revisions to our financial projections and fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1085611/oncopeptides-q4-germany-drives-sales?utm_source=finwire&utm_medium=RSS

Nyheter om Oncopeptides

Läses av andra just nu

Om aktien Oncopeptides

Senaste nytt